康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09966 康宁杰瑞制药-B

已收盘 08-19 16:08:48

8.135

+0.070

+0.87%

最高8.450	最低8.000	成交量138.20万
今开8.015	昨收8.065	日振幅5.58%
总市值78.83亿	流通市值78.83亿	总股本9.69亿
成交额1,126万	换手率0.14%	流通股本9.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"康宁杰瑞制药-B","latestPrice":8.135,"timestamp":1787126928010,"preClose":8.065,"halted":0,"volume":1382000,"delay":0,"changeRate":0.008679479231246161,"floatShares":969000000,"shares":969000000,"eps":-0.13964159954827424,"marketStatus":"已收盘","change":0.07,"latestTime":"08-19 16:08:48","open":8.015,"high":8.45,"low":8,"amount":11264315,"amplitude":0.055797,"askPrice":8.165,"askSize":1000,"bidPrice":8.12,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.13964159954827424,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787189400000},"marketStatusCode":5,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":8.065,"openAndCloseTimeList":[[1787103000000,1787112000000],[1787115600000,1787126400000]],"volumeRatio":1.803236,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966","defaultTab":"news","newsList":[{"id":"2660246906","title":"康宁杰瑞制药与石药集团合作开发的新药联合疗法上市申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2660246906","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660246906?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:31","pubTimestamp":1787049060,"startTime":"0","endTime":"0","summary":"8月18日，康宁杰瑞制药（09966）发布公告，公司与石药集团（01093）附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛一线治疗不可切除或转移性人类表皮生长因子受体2阳性成人乳腺癌的新药上市申请已获受理，并纳入优先审评审批程序。本次新药上市申请主要是基于一项关键III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844683914.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183844683914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999004220.SGD","LU1226288253.USD","01093","LU2039709279.SGD","LU0880133367.SGD","IE00B543WZ88.USD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU1152091168.USD","HK0000165453.HKD","IE00BZ08YR35.GBP","IE0008368742.USD","LU1328277881.USD","LU0140636845.USD","IE00B031HY20.USD","LU0314109678.HKD","BK1191","BK1574","IPOS","LU0315179316.USD","LU1152091754.HKD","LU0067412154.USD","LU1807302812.USD","LU1960683339.HKD","LU1008478684.HKD","LU1226287875.USD","LU1813983027.USD","BK1521","LU1993786604.SGD","LU0072913022.USD","LU0326950275.SGD","LU1226287529.USD","LU1226288170.HKD","LU0501845795.SGD","IE0008369823.USD","KURE","LU1951186391.HKD","BK1515","IE00B5MMRT66.SGD","09966","BK1161","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165144425","title":"康宁杰瑞制药-B：恩沃利单抗（KN026）联合HB1801治疗HER2阳性晚期乳腺癌新药申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1165144425","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165144425?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:02","pubTimestamp":1787047322,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B传来重磅消息——其自主研发的恩沃利单抗与HB1801联用方案，针对HER2阳性晚期乳腺癌适应症的新药上市申请，已正式获得中国国家药品监督管理局受理。对于HER2阳性晚期乳腺癌患者而言，这无疑是一则令人振奋的积极信号。据悉，此次获受理的适应症聚焦于HER2阳性晚期乳腺癌，该领域长期存在未被满足的临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153045285","title":"康宁杰瑞制药-B（09966）拟于2026年8月27日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1153045285","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153045285?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:43","pubTimestamp":1786524186,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（09966）8月12日公告，公司董事会将于2026年8月27日（星期四）召开会议，主要议程包括审议并通过公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布，以及处理其他事项。\n董事会名单显示，董事长兼执行董事为徐霆博士，执行董事为刘阳女士；非执行董事为左敏先生；独立非执行董事包括吴冬先生、黄欣琪女士及高翔博士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969303","title":"港股异动 | 康宁杰瑞制药-B(09966.HK)再涨超4% 与Pathos达成海外授权许可协议 核心资产实现出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969303","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969303?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:33","pubTimestamp":1786419186,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658675985","title":"港股异动 | 康宁杰瑞制药-B(09966.HK)尾盘涨近6% JSKN016达成海外授权 机构看好认股权证潜在增值空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2658675985","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658675985?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:08","pubTimestamp":1786345732,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123924648","title":"康宁杰瑞制药-B更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1123924648","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123924648?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:12","pubTimestamp":1785921127,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年8月5日发布2026年7月股份变动月报表，显示公司本月无新增发行及股份变动，股本结构保持稳定。公司公告披露，截至2026年7月末，康宁杰瑞制药-B法定注册股本仍为25,100,000,000股普通股，每股面值0.000002美元，法定/注册股本合计50,200美元。此外，公司已发行股份总数仍为968,506,697股，库存股份数目维持5,875,000股，两者合计总数与上月底相同，为974,381,697股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126409228","title":"恒指、国企指数转跌，科指升幅收窄，医药股、黄金有色股、半导体股逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=1126409228","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126409228?lang=zh_cn&edition=full","pubTime":"2026-08-05 09:50","pubTimestamp":1785894601,"startTime":"0","endTime":"0","summary":"恒生指数、国企指数转跌，恒生科指升幅收窄。医药股、黄金有色股、半导体股逆市上扬，中国黄金国际升 6%， 华虹宏力、中芯国际升 4%，康宁杰瑞制药升 3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07200","HSI","83115","03419","03115","09966","09115","82800","07300","07500","02099","02800","03037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114796098","title":"康宁杰瑞制药-B（09966）与石药集团合作开发之安尼妥单抗新辅治疗HER2阳性乳腺癌NDA获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1114796098","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114796098?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:06","pubTimestamp":1785838018,"startTime":"0","endTime":"0","summary":"2026年8月4日，康宁杰瑞制药-B发布自愿公告称，其与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛用于人类表皮生长因子受体2阳性早期或局部晚期乳腺癌新辅辅助治疗的新药上市申请，已获国家药品监督管理局受理，并被纳入优先审评审批程序。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656534133","title":"康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)新辅助治疗HER2阳性乳腺癌的新药上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2656534133","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656534133?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:02","pubTimestamp":1785837764,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 公布，与石药集团附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛用于人类表皮生长因子受体2阳性早期或局部晚期乳腺癌新辅助治疗的新药上市申请已获中国国家药品监督管理局受理，并纳入优先审评审批程序。研究结果表明，安尼妥单抗联合 HB1801±卡铂新辅助治疗HER2+早期或局部晚期乳腺癌，较现有标准治疗，可显著提升总体病理完全缓解率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475834.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IPOS","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656963586","title":"康宁杰瑞制药-B早盘涨超12% TROP2/HER3双抗ADC授权出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2656963586","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656963586?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:54","pubTimestamp":1785808440,"startTime":"0","endTime":"0","summary":"模拟交易客户端康宁杰瑞制药-B早盘涨超12%，截至发稿，股价上涨12.43%，现报8.32港元，成交额762.18万港元。康宁杰瑞生物制药宣布，其全资子公司江苏康宁杰瑞生物制药有限公司与Pathos AI， Inc．就康宁杰瑞自主研发的同类首创新药TROP2/HER3双特异性抗体偶联药物JSKN016达成授权许可协议。作为本次授权合作的一部分，康宁杰瑞获得Pathos授予的一份认股权证，有权认购Pathos的优先股股份，认购总价为6，250万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-04/doc-inimchzt5433129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","ADC","09966","BK1161","BK4231","BK4080","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195316571","title":"港股直击｜医药及医药外包股、半导体股、SaaS股、光通信股全线上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=1195316571","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195316571?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:42","pubTimestamp":1785807760,"startTime":"0","endTime":"0","summary":"港股医药及医药外包股、半导体股、SaaS股、光通信股全线上扬， $康宁杰瑞制药-B(09966)$、 $药明康德(02359)$升 12%， $剑桥科技(06166)$升 8%， $华虹宏力(01347)$升 4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/8a1a8c5698b6f32ee1637556a15bb35b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8a1a8c5698b6f32ee1637556a15bb35b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01347","09966","06166","02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656586892","title":"港股异动 | 康宁杰瑞制药-B(09966.HK)涨超11% TROP2/HER3双抗ADC授权出海 里程碑金额最高达20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656586892","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656586892?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:33","pubTimestamp":1785807231,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656583187","title":"康宁杰瑞制药-B(09966.HK)：JSKN016实现海外独家许可，里程碑总金额最高达20.93亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656583187","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656583187?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:27","pubTimestamp":1785803221,"startTime":"0","endTime":"0","summary":"格隆汇8月4日丨康宁杰瑞制药-B发布公告，2026年8月3日，公司全资附属公司江苏康宁杰瑞生物制药有限公司与Pathos AI, Inc.就JSKN016订立一项许可协议。据此，江苏康宁杰瑞向Pathos AI授出独家许可，以于中国内地、香港、澳门及台湾以外的地区研究、开发、制造及商业化JSKN016。倘若集团选择行使认股权证，相关投资安排及文件将另行签署并予以披露。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260804/32325121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121911469","title":"康宁杰瑞制药-B：江苏康宁杰瑞将从Pathos AI获1.25亿美元首付款，总交易额可达20.9亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121911469","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121911469?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:07","pubTimestamp":1785802034,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（ALPHAMAB-B）旗下江苏康宁杰瑞，近期与Pathos AI达成重磅合作。根据协议，江苏康宁杰瑞将获得一笔1.25亿美元的首付款。而整个交易的总潜在价值，最高可触及20.9亿美元之巨。这一数字，不仅彰显了合作伙伴对康宁杰瑞研发实力的高度认可，也预示着未来深度协作的广阔前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150425237","title":"康宁杰瑞制药-B（09966）授权Pathos AI全球开发JSKN016　可获最高20.93亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1150425237","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150425237?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:06","pubTimestamp":1785801984,"startTime":"0","endTime":"0","summary":"8月4日，康宁杰瑞制药-B（09966）发布自愿公告称，其全资子公司江苏康宁杰瑞生物制药有限公司已于2026年8月3日与Pathos AI, Inc.签署《许可协议》，就自主研发的双特异性抗体偶联药物（ADC）JSKN016达成境外独家许可合作。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656588259","title":"康宁杰瑞制药-B(09966.HK)与PATHOS AI就JSKN016订立一项许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2656588259","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656588259?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:06","pubTimestamp":1785801979,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125095231","title":"Pathos AI 与 Alphamab Oncology（康宁杰瑞制药-B）就全球首创 Trop2/Her3 双特异性 ADC 药物 Jskn016 达成全球授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1125095231","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125095231?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:04","pubTimestamp":1785801849,"startTime":"0","endTime":"0","summary":"Pathos AI 近日宣布与 Alphamab Oncology（康宁杰瑞制药-B）签署了一项全球授权协议。此次合作的核心是 Jskn016——一款全球首创的 Trop2/Her3 双特异性抗体偶联药物（ADC）。该协议标志着双方在创新抗癌疗法领域迈出了关键一步，旨在共同推动这款候选药物的全球开发与商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124637114","title":"康宁杰瑞制药-B：子公司授权Pathos AI独家商业化JSKN016，覆盖中国大陆、港、澳、台以外地区","url":"https://stock-news.laohu8.com/highlight/detail?id=1124637114","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124637114?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:03","pubTimestamp":1785801807,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（ALPHAMAB-B）发布公告，其子公司已授予Pathos AI一项独家许可，用于在中国大陆、香港、澳门及台湾以外的区域开发和商业化JSKN016。这一战略举措，旨在将这款创新药物的市场版图延伸至全球范围。通过授权协议，Pathos AI将获得特定区域的独家权利，从而推动JSKN016的国际化进程。此举不仅彰显了康宁杰瑞对自身研发实力的信心，也体现了其全球布局的雄心。而Pathos AI则凭借其人工智能驱动的药物开发平台，有望加速该药物的临床开发与市场准入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174418791","title":"康宁杰瑞制药-B：JSKN033获国家药监局药审中心批准，即将启动宫颈癌III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1174418791","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174418791?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:50","pubTimestamp":1785765048,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（Alphamab-B）宣布，其研发的JSKN033已获得国家药品监督管理局药品审评中心（CDE）的批准，即将启动一项针对宫颈癌治疗的III期临床研究。这一里程碑式的进展，标志着公司在肿瘤免疫治疗领域迈出了关键一步。该研究旨在进一步评估JSKN033在宫颈癌患者中的疗效与安全性，为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656374006","title":"康宁杰瑞制药-B(09966.HK)：JSKN033获CDE同意开展一项治疗宫颈癌的III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374006","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656374006?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:47","pubTimestamp":1785764820,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":-0.0573},{"period":"1month","weight":0.1604},{"period":"3month","weight":-0.0567},{"period":"6month","weight":-0.0969},{"period":"1year","weight":-0.1608},{"period":"ytd","weight":-0.177}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.037},{"period":"3month","weight":-0.007},{"period":"6month","weight":-0.0462},{"period":"1year","weight":0.0117},{"period":"ytd","weight":-0.0062}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。该公司高度差异化的内部管线由处于不同研发阶段的ADCs、单克隆抗体及双特异性抗体肿瘤药物组成。该公司的候选药物包括KN046（PD-L1/CTLA-4双特异性抗体）, KN026（抗HER2双特异性抗体）, KN035（皮下注射PD-L1）, JSKN003（HER2双表位ADC）等，用于1L sq NSCLC、乳腺癌 2+HER L1、晚期实体瘤、HER2表达实体瘤等适应症。","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.117313},{"month":2,"riseRate":0.571429,"avgChangeRate":0.192959},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.039472},{"month":4,"riseRate":0.857143,"avgChangeRate":0.098183},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.031094},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.059361},{"month":7,"riseRate":0.428571,"avgChangeRate":0.061567},{"month":8,"riseRate":0.428571,"avgChangeRate":0.030717},{"month":9,"riseRate":0.333333,"avgChangeRate":0.158319},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.030396},{"month":11,"riseRate":0.5,"avgChangeRate":0.042537},{"month":12,"riseRate":0.5,"avgChangeRate":-0.017716}],"exchange":"SEHK","name":"康宁杰瑞制药-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康宁杰瑞制药-B,09966,康宁杰瑞制药-B股票,康宁杰瑞制药-B股票老虎,康宁杰瑞制药-B股票老虎国际,康宁杰瑞制药-B行情,康宁杰瑞制药-B股票行情,康宁杰瑞制药-B股价,康宁杰瑞制药-B股市,康宁杰瑞制药-B股票价格,康宁杰瑞制药-B股票交易,康宁杰瑞制药-B股票购买,康宁杰瑞制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}